Antares Pharma, Inc. (ATRS) financial statements (2023 and earlier)

Company profile

Business Address 100 PRINCETON SOUTH
EWING, NJ 08628
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:65,91353,13745,72127,89231,55527,71547,911
Cash and cash equivalents65,91353,13723,20127,89226,56227,71532,899
Short-term investments1,245 22,520 4,993 15,012
Other undisclosed cash, cash equivalents, and short-term investments(1,245)      
Receivables83,00842,22135,07418,97611,8789,0737,952
Inventory, net of allowances, customer advances and progress billings11,54418,21616,00011,3509,2755,3275,724
Inventory11,54418,21616,00011,3509,2755,3275,724
Contract with customer, asset8,0308,1408,23510,442
Deferred costs    5051,7731,199
Other undisclosed current assets5,7774,8773,4162,6482,3231,3763,274
Total current assets:174,272126,591108,44671,30855,53645,26466,061
Noncurrent Assets
Operating lease, right-of-use asset3,7744,6215,463
Property, plant and equipment26,01524,02015,96114,89516,15817,86714,793
Intangible assets, net (including goodwill)18,9748,7881,5731,9262,4963,1403,530
Goodwill1,0951,0951,0951,0951,0951,0951,095
Intangible assets, net (excluding goodwill)17,8797,6934788311,4012,0452,435
Deferred income tax assets33,04346,982 
Other noncurrent assets1,4271,5291,30814814854178
Total noncurrent assets:83,23385,94024,30516,96918,80221,06118,501
TOTAL ASSETS:257,505212,531132,75188,27774,33866,32584,562
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities52,09941,82929,42823,13212,93913,75811,676
Accounts payable17,05616,19412,90511,1355,9577,8855,188
Accrued liabilities35,04325,63516,52311,9976,9825,8736,488
Deferred revenue4,4273,9431,738
Debt1,50016,2301,2493,043   
Deferred revenue and credits2,7946,1495,144
Contract with customer, liability1,018
Other undisclosed current liabilities9041,203     
Total current liabilities:58,93063,20532,41527,19315,73319,90716,820
Noncurrent Liabilities
Long-term debt and lease obligation22,81729,48545,83622,08324,858  
Long-term debt, excluding current maturities18,24124,66940,39522,08324,858  
Operating lease, liability4,5764,8165,441
Liabilities, other than long-term debt 726  2001,200700
Deferred revenue and credits2001,200700
Other liabilities 726     
Other undisclosed noncurrent liabilities(4,576)      
Total noncurrent liabilities:22,81730,21145,83622,08325,0581,200700
Total liabilities:81,74793,41678,25149,27640,79121,10717,520
Stockholders' equity
Stockholders' equity attributable to parent, including:175,758119,11554,50039,00133,54745,21967,043
Additional paid in capital351,079340,756332,377314,907302,965297,826295,292
Accumulated other comprehensive loss(685)(683)(702)(703)(700)(714)(692)
Accumulated deficit(176,337)(222,626)(278,827)(276,800)(270,285)(253,445)(229,107)
Other undisclosed stockholders' equity attributable to parent1,7011,6681,6521,5971,5671,5521,548
Total stockholders' equity:175,758119,11554,50039,00133,54745,21967,043
TOTAL LIABILITIES AND EQUITY:257,505212,531132,75188,27774,33866,32584,562

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues183,982149,599123,86463,55454,51552,22245,658
Revenue, net54,51552,22245,658
Cost of revenue(106,872)(63,078)(50,475)(31,065)(27,466)(28,817)(19,458)
Cost of goods and services sold(359)(356)(50,475)(31,065)(27,466)(28,817)(19,458)
Gross profit:77,11086,52173,38932,48927,04923,40526,200
Operating expenses(49,768)(72,902)(72,397)(36,590)(43,500)(47,522)(46,662)
Other undisclosed operating income38,591      
Operating income (loss):65,93313,619992(4,101)(16,451)(24,116)(20,462)
Nonoperating expense(3,662)(3,698)(3,019)(2,414)(292)(122)(22)
Foreign currency transaction loss, before tax     (3)(48)
Other nonoperating income (expense)(51)89530261271(199)(34)
Interest and debt expense(3,611)(3,787)(3,549)(2,675)(1,423)  
Income (loss) from continuing operations before equity method investments, income taxes:58,6606,134(5,576)(9,190)(18,166)(24,239)(20,484)
Other undisclosed income from continuing operations before income taxes3,6113,7873,5492,6751,423  
Income (loss) from continuing operations before income taxes:62,2719,921(2,027)(6,515)(16,743)(24,239)(20,484)
Income tax expense (benefit)(15,982)46,280   (100)(175)
Net income (loss) available to common stockholders, diluted:46,28956,201(2,027)(6,515)(16,743)(24,339)(20,659)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):46,28956,201(2,027)(6,515)(16,743)(24,339)(20,659)
Other comprehensive income (loss)(2)191(3)15(22)14
Comprehensive income (loss), net of tax, attributable to parent:46,28756,220(2,026)(6,518)(16,728)(24,361)(20,645)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: